trending Market Intelligence /marketintelligence/en/news-insights/trending/OXUQT5w4jngKsiDm43OqYQ2 content esgSubNav
In This List

Ono Pharmaceutical secures license for 2 cancer compounds

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector

Blog

Insight Weekly: Energy reforms after midterms; Crisis ends 'age of gas'; bank deposits fall


Ono Pharmaceutical secures license for 2 cancer compounds

Ono Pharmaceutical Co. Ltd. secured an exclusive license to develop and commercialize certain Karyopharm Therapeutics Inc. compounds for cancer in Japan, South Korea, Taiwan, Hong Kong and the Association of Southeast Asian Nations.

Ono will make a one-time upfront payment of ¥2.5 billion for the license to Selinexor and KPT-8602 which are currently under clinical development.

The company is also required to pay up to an additional ¥19.15 billion if certain development and commercial milestones are achieved as well as royalties once the drugs hit the market.

Karyopharm retains the rights to develop and commercialize the products outside the Ono territory.

As of Oct. 11, US$1 was equivalent to ¥112.28.